Clinical Trials

39 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05801913 2026-03-05

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell

NCT07451054 2026-03-05

CD45BE-HSPC + CART-45 Cells

42 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05432635 2026-02-23

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03029338 2026-02-11

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

20 enrolled

Lymphoma, Recurrence, Lymphoma, B-Cell

NCT07398963 2026-02-10

Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma

48 enrolled

Lymphoma, B-Cell

NCT00586391 2026-02-06

CRETI-NH

14 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05149391 2026-01-30

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

3 enrolled

Lymphoma, B-Cell

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

23 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT07367685 2026-01-26

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

6 enrolled

Lymphoma, B-Cell

NCT07049432 2026-01-23

CARMEN-803

13 enrolled

Lymphoma, B-Cell

NCT07334574 2026-01-13

XP-006

20 enrolled

Lymphoma, B-Cell

NCT07335328 2026-01-13

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Lymphoma, B-Cell

NCT07316920 2026-01-06

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

19 enrolled

Recurrence, Lymphoma, B-Cell

NCT05098613 2025-12-24

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

68 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07166549 2025-12-24

BaseCAR-01

12 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04077307 2025-12-19

MAATEO

LymphoidOther hematologic neoplasmPlasma cell

9 enrolled

Leukemia, Multiple Myeloma, Lymphoma, B-Cell

NCT06208735 2025-12-15

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02650414 2025-12-12

CD22 Redirected Autologous T Cells for ALL

41 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

19 enrolled

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT06824701 2025-12-03

TARZAN

Recurrence, Lymphoma, B-Cell

NCT05618327 2025-12-02

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

104 enrolled

Lymphoma, B-Cell

NCT06295549 2025-12-01

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Terminated

11 enrolled

Recurrence, Lymphoma, B-Cell

NCT06707259 2025-11-20

Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL

Lymphoma, B-Cell

NCT07234045 2025-11-18

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

30 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT07053670 2025-11-17

CT1190B

27 enrolled

Lymphoma, B-Cell

NCT05773040 2025-11-10

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

33 enrolled

Lymphoma, Lymphoma, B-Cell

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05270057 2025-10-09

LONCA

11 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02153580 2025-10-06

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

37 enrolled

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Phase 1 Enrolling by invitation

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT07168486 2025-09-11

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04410900 2025-09-08

Vaccine Responsiveness After CAR-T Cell Therapy

49 enrolled

Infections, Lymphoma, B-Cell

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

52 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06027957 2025-08-26

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07072169 2025-07-18

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

56 enrolled

Lymphoma, B-Cell

NCT07068906 2025-07-16

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

27 enrolled

Lymphoma, B-Cell

NCT04419909 2025-07-02

Retreatment With CTL019/CTL119

12 enrolled

Lymphoma, B-Cell

NCT03774654 2025-07-01

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

13 enrolled

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04892277 2025-07-01

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04088890 2025-06-10

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

52 enrolled

Lymphoma, B-Cell

NCT04317885 2025-05-23

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

25 enrolled

Lymphoma, B-Cell

NCT04655677 2025-05-23

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

10 enrolled

Lymphoma, B-Cell

NCT04240808 2025-05-15

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

10 enrolled